BioCentury
ARTICLE | Clinical News

Avera's gantacurium meets Phase II endpoint

June 28, 2006 12:57 AM UTC

Avera (San Diego, Calif.) said gantacurium ( AV430A) achieved more than 90% acceptable intubations at 60 seconds after injection, the primary endpoint, in a Phase II trial as an adjunct to anesthesia ...